Stray Dog

Noom launches OpenRx peptides brand, rival to HIMS

  • Bad news: Noom's new OpenRx brand fully overlaps two HIMS Peptides+ products, NAD+ and sermorelin, and went live earlier.
  • Bad news: Noom also launched a screenless wristband, copying the HIMS platform path of testing, peptides and wearables.
  • Mixed: HIMS can stand out only through its own US factory, user data and subscription cross-selling, and its first-mover window is short.
Read the full notes

Noom launched a standalone brand, OpenRx, on 17 Nov. Two of its first products overlap fully with HIMS Peptides+, and it went live earlier. Noom also launched the Noom Band, a screenless wristband, copying the HIMS platform path of behaviour change, at-home testing, peptides and wearables.

Read more

HIMS can differentiate in peptides only through its own US factory, user data and subscription cross-selling, and its first-mover window is short. Whether the moat holds depends on whether scale and the data loop come through first.

Key evidence

  • Noom's official press release on 17 Nov launched the standalone brand OpenRx. First products: injectable sermorelin (muscle), injectable NAD+ (energy), and two dissolvable tablets containing PT-141, oxytocin and tadalafil (sexual health)
  • Two products overlap fully with the first batch of HIMS Peptides+ due in late November (NAD+, sermorelin, glutathione, B12): NAD+ and sermorelin. Noom is live earlier
  • Noom's chief medical officer has said publicly that the company is evaluating BPC-157 and TB-500, the two products we favour most, which await regulatory clearance
  • Fulfilment differs: Noom uses an external network of 503A compounding pharmacies, while HIMS has its own US peptide factory
  • HIMS's branded weight-loss drug gross margin has been squeezed from 74% to 57%, and peptides are a hedge with high gross margin
  • The barrier to entering peptides is low: Ro, Noom and longevity clinics can all do it
Show 3 more
  • Noom Band, 16 Nov (Fitt Insider): a screenless wristband made with Sensor Bio, given out free in employer metabolic health programmes, collecting heart rate, HRV, blood oxygen, sleep and activity data
  • HIMS has already connected to smart scales, and Dudum has previewed its own monitoring device. This closely resembles Noom's route of at-home blood collection and wearable integration
  • SEC EDGAR, 17 Nov: all nine Form 4s relate to quarterly RSU vesting and tax withholding on 13 Nov (codes M/F). The Form 4s matching three Form 144s have not yet been filed, so no judgement for now

Catalysts to watch

  • HIMS Peptides+ goes live in late November with pricing and gross margin disclosed, testing the cost, supply and quality control advantages of its own factory
  • Regulatory clearance of BPC-157 and TB-500, with Noom, Ro and longevity clinics entering at the same time
  • Launch of the HIMS monitoring device Dudum has previewed
  • Disclosure of Peptides+ user numbers and the subscription cross-sell conversion rate
  • Once the Form 4s matching the Form 144s are filed, a read on the insider selling

Risks

  • Noom OpenRx is live earlier and two products overlap, weakening HIMS's first-mover advantage
  • The barrier to entry in peptides is low and Ro and longevity clinics can do the same, so the category alone cannot build a moat
  • Noom is copying the HIMS platform path (behaviour change, at-home testing, peptides, wearables), which puts the 'accumulated user health data' moat in doubt
  • The cost and quality control advantages of HIMS's own US factory are not yet validated by data
  • Branded weight-loss drug gross margin has fallen from 74% to 57%, so the window for the high-margin peptide hedge is tight

Sources 3

  1. Noom official press release (noom.com, OpenRx launch, 17 Nov)
  2. Fitt Insider (Noom Band wearable, 16 Nov)
  3. SEC EDGAR (nine Form 4s and three Form 144s, 17 Nov)